Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension

Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug

(2017) Stavroula Nanaki et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Does Half-Life Matter After Antipsychotic Discontinuation?

(2017) Peter J. Weiden et al.   JOURNAL OF CLINICAL PSYCHIATRY

Adherence to Antipsychotic Therapy: Association With Hospitalization and Medicare Spending Among Part D Enrollees With Schizophrenia

(2017) Pamela Roberto et al.   PSYCHIATRIC SERVICES

Paliperidone for the treatment of schizoaffective disorder

(2016) Larry Alphs et al.   EXPERT OPINION ON PHARMACOTHERAPY

The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension

(2016) Nicolas Darville et al.   JOURNAL OF CONTROLLED RELEASE

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis

(2016) Asta R Prajapati et al.   BMJ Open

Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat

(2015) Nicolas Darville et al.   TOXICOLOGIC PATHOLOGY

Comparative Pharmacology of Risperidone and Paliperidone

(2015) Maria Corena-McLeod   Drugs in research & development

Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size

(2014) Donglei Leng et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

(2014) Adriaan Cleton et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Intramuscular Administration of Paliperidone Palmitate Extended-Release Injectable Microsuspension Induces a Subclinical Inflammatory Reaction Modulating the Pharmacokinetics in Rats

(2014) Nicolas Darville et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment

(2012) Debbi A. Morrissette et al.   CNS SPECTRUMS

Influence ofABCB1genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects withCYP2D6*10/*10

(2011) Hee-Doo Yoo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania

(2010) Carla M Canuso et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers

(2010) Jesús Novalbos et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

(2009) Mahesh N. Samtani et al.   CLINICAL PHARMACOKINETICS

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

(2009) Luca Pani et al.   Expert Opinion on Drug Delivery

Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release

(2009) Sandra Boom et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives

(2008) Nuggehally R. Srinivas   BIOMEDICAL CHROMATOGRAPHY